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Background: Acute lymphoblastic leukemia is the most common 
cancer in children. In developed countries, overall survival rates 
are around 80%, while in developing countries, survival rate is 
much lower due to high rates of relapse, and abandonment and 
complications arising from the disease treatment. 
Objectives: To assess induction mortality, relapse and treatment 
abandonment. To describe the most frequent side effects of 
chemotherapy. To evaluate survival rates of patients and compare the 
findings found in this study with the existing literature. 
Material and methods: A retrospective cohort study was conducted 
on patients aged 1 to 18 with acute lymphoblastic leukemia, 
who received treatment under the BFM ALL IC 2009 protocol at 
Fundación Hospital La Misericordia (HOMI), from November 2012 
to December 2014. 
Results: 119 patients were included. Death occurred in two cases 
during induction (1.67%) and in nine (7.7%) due to treatment, all 
of them caused by infection/sepsis and in complete remission. Six 
patients abandoned treatment (5%), while seven relapses  occurred 
(5.9%). All patients experienced some type of side effect related to 
chemotherapy, the most frequent being febrile neutropenia (41.2%) 
and grade 3-4 infections (15.8%). Overall survival and event-free 
survival rates were 79.9% and 73.3%, respectively. 
Conclusions: Evaluating complications of treatment and death allows 
adopting measures and strategies to reduce such complications.
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| Resumen |
Introducción. La leucemia linfoblástica aguda es el cáncer más 
frecuente en los niños. La sobrevida en países desarrollados está 
alrededor de 80%, mientras que en países de bajos ingresos la 
tasa de supervivencia es menor debido a altas cifras de recaída, 
abandono de tratamiento y complicaciones relacionadas con el 
tratamiento.
 
Objetivos. Hacer una evaluación de muerte en inducción relacionada 
con el tratamiento, las recaídas y los abandonos de tratamiento; 
describir las reacciones adversas más observadas relacionadas 
con medicamentos de quimioterapia; evaluar la sobrevida, y comparar 
los hallazgos con publicaciones previas.
Materiales y métodos. Estudio de cohorte retrospectivo. Se incluyeron 
pacientes con edades entre 1 y 18 años, con diagnóstico de leucemia 
linfoblástica aguda tratada entre noviembre de 2012 y diciembre de 
2014 en la Fundación Hospital La Misericordia de Bogotá (HOMI) 
y a quienes se les había aplicado tratamiento con el protocolo BFM 
ALL IC 2009. 
Resultados. Se incluyeron 119 pacientes. Se presentaron dos (1.67%) 
muertes en inducción y nueve (7.7%) relacionadas con tratamiento 
—todas por infección/sepsis y en remisión completa—, seis abandonos 
(5%) y siete recaídas (5.9%). Todos los pacientes presentaron algún tipo 
de reacción adversa relacionada con medicamentos de quimioterapia, 
las más frecuentes fueron neutropenia febril (41.2%) e infecciones 
grado 3-4 (15.8%). Las sobrevidas global y libre de evento fueron de 
79.9% y 73.3%, respectivamente. 
Conclusiones. La evaluación de los efectos deletéreos del tratamiento 
y muerte durante tratamiento permiten tomar medidas para disminuir 
estas complicaciones.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common neoplasm 
in pediatric patients (1). Overall cure rates for childhood ALL have 
improved over the years and current survival rates vary from 75% 
to 85% in patients treated in high-income countries (2); with the 
continuous improvement of survival rates, the goal of current 
clinical protocols is to reduce adverse reactions related to treatment 
(3). In contrast, in low-income countries, the possibilities of cure 
are lower, probably due to disease status at diagnosis, treatment 
abandonment, high rates of relapse and death caused by toxicity or 
side effects related to treatment (2). 
In Colombia, the Cancer Registry of Cali (RPCC by its acronym in 
Spanish) reported a rate of 41% of survival in children with leukemia 
between 1994 and 2003 (4); the Protocol of Public Health Surveillance on 
Childhood Cancer reported that high mortality in children with leukemia 
is given by deaths during the first year of treatment, possibly because 
of poor access to treatment, low intensity treatment and toxicity caused 
by it. It also mentions that the causes of such low survival rates have 
not been identified, so intervention on them has not been possible (5). 
Better cure rates are affected by additional barriers; the evaluation 
in children with ALL by Suarez et al. in Bogotá (6) reports that delays 
due to non-medical reasons in treatment are common and predict 
treatment failure. The same study also reported mortality during 
induction of 7%, death in complete remission of 3% and abandonment 
rates of 9% (6). According to information provided by the National 
Institute of Health of Colombia, 455 new cases of ALL were confirmed 
in 2013, with an overall mortality related to treatment of 15.6% (7).
In a study conducted in Central America, specifically in low-
income countries, overall mortality related to treatment of 9.3% and 
mortality during induction of 5.5% were described (2). 
Within the International BFM Study Group (Berlin-Frankfurt-
Münster) (I-BFM-SG), the ALL strategy committee has developed 
several protocols with optimal clinical results over the last 20 
years, most of them derived from the original BFM. Chemotherapy 
treatments proposed by the BFM for resource-limited countries 
have some changes aimed at local needs and conditions. In 2007, an 
amendment to the Intercontinental BFM 2002 Protocol was defined 
as more suitable for the diagnosis and treatment of children with ALL 
in Colombia (8). This protocol was adapted and applied for about five 
years at Fundación Hospital La Misericordia in Bogotá (Fundación 
HOMI), referral center for care of children with ALL in Colombia.
In 2012, the implementation of a modified version of the “Protocol for 
study and treatment of childhood lymphoblastic leukemia, ALL PINDA 
2009, ALL IC BFM 2009” was decided. This approach to treatment is 
the same currently used in Argentina, Uruguay, Chile and Colombia, 
where the protocol is conducted by the National Cancer Institute.
In 2014, the BFM group published their experience with the BFM 
ALL IC 2002 treatment protocol, showing results from 15 countries 
of three continents, most of them with average incomes, as in the case 
of Colombia. The results of the implementation of this protocol show 
an improvement in the outcome of treatment for ALL, with event-free 
survival of 74% and overall survival of 82% (9).
There are no publications in Colombia that evaluate the results 
obtained with this type of treatment strategies, including survival and 
deleterious effects. This work aims at conducting an interim assessment 
of death during induction, treatment-related death (in remission), 
relapse and treatment abandonment, as well as at describing the 
most frequent adverse reactions observed with chemotherapy drugs, 
assessing overall and general event-free survival rates, and comparing 
—by risk group— previous outcomes with previous reports to assess 
the results of the implementation of this protocol at the institution. 
Materials and methods
The description of a cohort of patients was performed. The inclusion 
criteria for the study were: age under 18, confirmed acute lymphoblastic 
leukemia diagnosis at Fundación HOMI between November 1, 2012 and 
December 31, 2014, treatment using the protocol BFM ALL IC 2009 
(Table 1) in the same institution and continuity in treatment during the 
time of evaluation; those who started treatment and abandoned are also 
included until the time of abandonment. Exclusion criteria included being 
diagnosed in other institutions and being transferred to Fundación HOMI 
to continue treatment. Information was collected from clinical records. 
This study was approved by the ethics committee of the institution 
prior to the review of the database, and the principle of privacy and 
confidentiality was preserved. Follow-up time was considered in 
months and was measured from the moment of diagnosis of the disease 
until the outcomes, which were defined as death during induction, death 
related to treatment, relapse, abandonment and transfer. The follow-
up was done until September 30, 2015 and lasted between 9 and 34 
months. The protocol was valid until the date of termination of the study.
Qualitative variables were presented as absolute and relative 
frequencies for the descriptive analysis. Similarly, a survival analysis 
was performed using Kaplan-Meier and Log Rank test for comparison 
of curves. High risk patients received prophylactic or therapeutic 
radiation accordingly to their condition.
Diagnosis
Diagnosis of ALL was confirmed with the presence 25% or more 
lymphoblasts in bone marrow. Flow cytometry based on EuroFlow 
panel criteria (10) was used for immunological classification of 
tumor cells, karyotype cytogenetic assessment was performed, and 
translocations t (12:21), t (4:11) and t (9:22) were identified with 
fluorescence in situ hybridization (FISH).The involvement of the central 
nervous system (CNS) was determined through identification of the 
cells using the cytospin method, for posterior classification according 
to the status:
Status 1: No clinical evidence disease, including facial paralysis that 
may be attributable to leukemia; no images —computerized axial 
tomography scan (CT scan) or magnetic resonance imaging (MRI) 
taken by suspicion— with evidence of CNS abnormalities attributable 
to leukemia, normal fundus or cerebrospinal fluid with no blasts and 
no other evidence of CNS leukemia.
Status 2: Blasts clearly identifiable in a CSF cytocentrifuge with cell 
count of <5/uL and CSF ratio of red blood cells (RBCs): leukocytes 
(LEU) ≤100:1; with this ratio between RBCs and LEU, a lumbar 
puncture is considered non-traumatic and CSF non-contaminated 
with blood. Lymphoblasts in a CSF cytocentrifuge and ratio GR: 
LEU> 100:1; with this ratio between erythrocytes and leukocytes, 
lumbar puncture is considered traumatic and CSF contaminated with 
blood or as a traumatic lumbar puncture —CSF contaminated with 
blood— associated with an initial leukocyte count of >50000/uL. 
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Prednisolone 60 mg/m2/d. Days 1-28
Vincristine 1.5 mg/m2/d. Days 8, 15, 22, 29
Daunorubicin 30 mg/m2/d. Days 8, 15 (22, 29 intermediate and high risk)
L asparaginase 5000 UI/m2/d. Days 12, 15, 18,  21, 24, 27, 30, 33
 Intrathecal therapy Methotrexate. Days 1, 12, 33
Phase Ib
Mercaptopurine 60 mg/m2/d. Days 36-63 (28 days)
Cyclophosphamide 1000 mg/m2/d. Days 36, 64
Mesna 1:1 cyclophosphamide
Cytarabine 75 mg/m2/d. Days 38-41, 45-48, 52-55, 59-62








Protocol mM (ALL B and T SR-IR) Block HR1 (x2) (ALL B and T HR)
Mercaptopurine 25 mg/m2/d. Days 1-56 Dexamethasone 20 mg/m2/d. Days 1-5
Methotrexate * 2 gr/m2/d every 14 days (x4). Days 8, 22, 36, 50 Vincristine 1.5 mg/m2/d. Days 1, 6
Calcium Folinate 15 mg/m2 (x3) 42, 48, 54 h after MTX Methotrexate 5 gr/m2/d. Day 1
Intrathecal therapy Methotrexate. Day 2 Calcium Folinate 15 mg/m2 (x3) 42, 48, 54 h after MTX
*5 gr/m2/day in ALL T SR-IR
Cyclophosphamide 200 mg/m2/d. Days 2 -4 every 12 hours. Five doses
Mesna 1:1 cyclophosphamide
Cytarabine 2000 mg/m2/d. Day 5 (2 doses total)
L asparaginase 25.000 UI/m2/d. Day 6
Intrathecal therapy MTX / Ara-C / Prednisone. Day 2
Block HR2 (x2) (ALL B and T HR) Block HR3 (x2) (ALL B and T HR)
Dexamethasone 20 mg/m2/d. Days 1-5 Dexamethasone 20 mg/m2/d. Days 1-5
Vincristine 1.5 mg/m2/d. Days 1 and 6 Cytarabine 2000 mg/m2/d. Days 1-2 every 12 hours. Four doses
Methotrexate 5 gr/m2/d. Day 1 Etoposide 100 mg/m2/d. Days 3-5 every 12 hours. Five doses
Calcium Folinate 15 mg/m2 (x3) 42, 48, 54 h after MTX L asparaginase 25.000 UI/m2/d. Day 6
Ifosfamide 800 mg/m2/d. Days 2-4 every 12 hours. Five doses Intrathecal therapy MTX / Ara-C / Prednisone. Day 2
Mesna 1:1 ifosfamide    
Daunorubicin 30 mg/m2/d. Day 5    
L asparaginase 25.000 UI/m2/d. Day 6    







Protocol II Phase A 
Dexamethasone 10 mg/m2/d. Days 1-21 
Vincristine 1.5 mg/m2/d. Days 8, 15, 22, 29
Doxorubicin 30 mg/m2/d. Days 8, 15, 22, 29
L asparaginase 10.000 UI/m2/d. Days 8, 11, 15, 18
Protocol II Phase B
Thioguanine 60 mg/m2/d. Days 36-49 (14 days)
Cyclophosphamide 1000 mg/m2/d. Day 36
Mesna 1:1 cyclophosphamide
Cytarabine 75 mg/m2/d. Days 38-41, 45-48




Intrathecal therapy Methotrexate (SR-IR x4) MTX / Ara-C / Prednisone (HR x6)
SR: standard risk; IR: intermediate risk; HR: high risk. Source: Own elaboration based on the data obtained in the study.
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Status 3: Abnormal mass in the brain and/or meninges detected 
through CT/MRI, cranial nerve palsies, regardless of origin; although 
CSF does not show blasts nor abnormal masses in the images, isolated 
compromise of the retina is evident but with CFS with no blasts nor 
masses in CT/MRI or a non-traumatic lumbar puncture with a cell 
count CSF>5/uL and most of the blasts in the cytocentrifuge.
Risk classification
Risk classification was established by the BFM group considering 
clinical and laboratory criteria evaluated in previous protocols; 
according to the characteristics described in Table 2, patients were 
classified as standard risk, intermediate risk and high risk.












>1 year and/or <6 
years













MRD in bone 
marrow on day 15
<0.1% <10% >10%
Bone marrow on 
day 15
M1 (<5% blasts by 
morphology) or M2 
(>5 y <25% blasts 
by morphology) 
M1 or M2 M3
Bone marrow on 
day 33
M1 (<5% blasts by 
morphology)
M1 M2 or M3
Molecular biology
Negative for t 
(9:22) (BCR/ABL) or 
t (4:11) (MLL/AF4)
Negative for t 
(9:22) (BCR/ABL) or 
t (4:11) (MLL/AF4)
Positive for t (9:22) 
(BCR/ABL) or t 
(4:11) (MLL/AF4) or 
hypodiploidy ≤45 
chromosomes
Source: Own elaboration based on the data obtained in the study protocol.
Outcomes
Treatment-related death, defined as death during induction or death 
in complete remission occurred; the first death was specified as death 
in the first 33 days of treatment and the second, as death after this 
period without clinical or paraclinical evidence of disease activity.
Secondary outcomes were abandonment, defined as the interruption 
of treatment for four or more weeks without medical reason, transfer 
to another institution due to the change of treatment center by the 
insurer, and relapse in bone marrow caused by the reappearance of 
lymphoblasts ≥25% in bone marrow. 
In the SNC, relapses were established by the appearance of cells 
>5/uL CSF and indisputable lymphoblasts identified in cytocentrifuge 
or intracerebral mass in CT/MRI without blasts in cerebrospinal fluid 
(CSF), peripheral blood (PB) or bone marrow (BM) —a biopsy may be 
necessary for diagnosis—. In the testicles, relapses were verified by a 
steady insensitive unilateral or bilateral increase of one or both testicles, 
with volume >2 and deviations measured with the Prader orchidometer 
—the diagnosis must be confirmed through biopsy— and combined by 
simultaneous compromise of two or more compartments or locations; 
BM relapse is considered compromised when >5% lymphoblasts. 
Another outcome was the description of adverse reactions to 
chemotherapy drugs, which were evaluated based on the criteria of the 
National Cancer Institute (NCI CTC v2.0): incidence of infections, 
defined as those with identified pathogen and antibiotic treatment and 
sepsis; incidence of cardiac, liver toxicity and mucositis grade 3 and 
4; requirement for admission to the intensive care unit and transfusion 
requirement, which includes transfusions of red blood cells, platelets, 
fresh frozen plasma and cryoprecipitate. 
Statistical analysis
The event-free and overall survival were estimated according to 
the Kaplan Meier method. Event-free survival was defined as the 
period between the start of treatment and presentation of an event 
(whichever comes first: death, relapse, second malignancy, transfer 
or abandonment), for those who have not presented any, the event 
was the last control alive. Overall survival was defined as the time 
between the start of treatment and the last control alive, regardless 
of the condition of the disease.
Results
The sample includes 119 patients who meet the inclusion criteria in 
the specified period. Demographic characteristics are shown in Table 3.
Mortality
Of 119 patients, two (1.67%) died during induction, nine (7.7%) 
died in remission related to treatment due to infection/sepsis, 
seven of them were classified as high risk, two as intermediate 
risk, and there were no deaths in those with standard risk. Deaths 
that occurred during the treatment stages were: two (18%) in 
phase Ib, two (18%) in block HR1#1, two (18%) in block HR 
3#1, one (10%) in HR3 block HR3#2 and two (18%) in protocol 
II phase A. 
Abandonment and relapse
Six abandonments (5%) and seven relapses occurred (5.9%), the 
latter in two high-risk patients and five in intermediate-risk patients. 
Five relapses (71.4%) were isolated bone marrow, one (14.3%) 
was isolated CNS and one (14.3%) was isolated testicular. In two 
patients, relapses occurred after completing treatment —at 30 and 
26 months after diagnosis—; one patient was considered high risk 
and the other intermediate risk. The remaining five patients —a 
high-risk patient and four-intermediate risk patients— relapsed 
within the first year of treatment.
Drug-related adverse reactions
A description of the adverse reactions related to chemotherapy drugs 
used in the treatment for each phase and risk group was made (Table 
4 and 5). 
All the patients had some adverse reactions related to 
chemotherapy drugs; the most frequent was febrile neutropenia 
during induction phase for all risks and in the consolidation phase 
for high risk patients. In the mM protocol, lower incidence 
of complications in general was found, as well as less febrile 
neutropenia, grade 3-4 infections and admission to the pediatric 
intensive care unit (PICU). The transfusion requirement was 
high in all groups of patients, especially in the induction phase.
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Table 3. Patient characteristics and results of initial treatment according to the risk group in the total population.
 
 
Total Standard risk Intermediate risk High risk
n % n % n % n 0,0712
Gender 119 100 11 100 73 100 35 100
Female 38 31.9 5 45.4 34 46.6 13 37.1
Male 81 68.1 6 54.6 39 53.4 22 62.9
Age 119 100 11 100 73 100 35 100
1-6 years 49 41.2 11 100.0 31 42.5 7 20.0
6-10 years 29 24.4 0 0.0 21 28.7 8 22.9
10-15 years 29 24.4 0 0.0 15 20.5 14 40.0
>15 years 12 10.0 0 0.0 6 8.3 6 17.1
Leukocyte count at diagnosis 119 100 11 100 73 100 35 100
<10,000 68 57.1 9 81.8 42 57.5 18 51.4
10.000-20.000 15 12.6 2 18.2 11 15.1 2 5.7
20.000-50.000 13 10.9 0 0.0 9 12.3 3 8.6
50.000-100.000 11 9.2 0 0.0 6 8.2 5 14.3
>100.000 12 10.0 0 0.0 5 6.8 7 20.0
CNS status 119 100 11 100 73 100 35 100
1 118 99.1 11 100.0 73 100.0 3. 4 97.0
2 0 0.0 0 0.0 0 0.0 0 0.0
3 1 0.9 0 0.0 0 0.0 1 3.0
Immunophenotype 119 100 11 100 73 100 35 100
B 108 90.7 11 100.0 68 93.1 29 82.9
T 11 9.3 0 0 5 6.9 6 17.1
Translocation 9:22 119 100 11 100 73 100 35 100
Negative 87 73.1 8 72.7 51 69.8 28 80
Positive 2 1.7 0 0.0 0 0.0 2 5.7
Not available 30 25.2 3 27.3 22 30.2 5 14.3
Translocation 4:11 119 100 11 100 73 100 35 100
Negative 80 67.2 7 63.6 46 63.0 27 77.1
Positive 0 0.0 0 0.0 0 0.0 0 0.0
Not available 39 32.8 4 36.4 27 37.0 8 22.9
Translocation 12:21 119 100 11 100 73 100 35 100
Negative 63 52.9 6 54.5 35 47.9 22 62.8
Positive 13 10.9 2 18.2 8 10.9 3 8.6
Not available 43 36.2 3 27.3 30 41.2 10 28.6
Kariotype 119 100 11 100 73 100 35 100
Normal 74 62.2 8 72.7 47 63.4 19 54.3
Hyperdiploid 8 6.7 0 0.0 5 6.8 3 8.6
Complex 9 7.6 0 0.0 5 6.8 4 11.4
Not available 28 23.5 3 27.3 16 23.0 9 25.7
Good 107 89.9 11 100.0 73 100.0 23 65.7
Poor 8 6.7 0 0.0 0 0.0 8 22.9
Not evaluable (debulking) 4 3.4 0 0.0 0 0.0 4 11.4
<1% 47 39.5 11 100.0 36 49.3 0 0.0
1-10% 38 31.9 0 0.0 36 49.3 2 5.7
>10% 32 26.8 0 0.0 0 0.0 32 91.4
Not available 2 1.8 0 0.0 1 1.4 1 2.9
Complete remission on day 33* 118 100 11 100 73 100 34 100
No 9 7.6 0 0.0 1 1.4 8 23.5
Yes 109 92.4 11 100.0 72 98.6 26 76.5
*<5% blasts by morphology. Source: Own elaboration based on the data obtained in the study.
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Table 4. Adverse reactions related to medication per treatment phase in protocol ALL IC BFM 2009.
Treatment phases 
IA IB mM Blocks IIA IIB
n % n % n % n % n % n %
Number of patients 119 100 116 100 74 100 26 100 94 100 89 100
Transfusional requirement 111 93.3 113 97.4 4 5.4 25 96.1 29 31 60 67.4
Thrombosis 11 9.2 1 0.9 0 0.0 4 15.4 1 1.1 0 0.0
Allergy * 0 0.0 3 2.6 0 0.0 14 53.8 2 2.1 0 0.0
Febrile neutropenia 72 60.5 98 84.5 7 9.4 26 100.0 61 65.1 32 35.9
Grade 3-4 infections 26 21.8 38 32.7 3 4.0 20 76.9 20 21.3 8 9.0
PICU 11 9.2 18 15.5 0 0.0 13 50.0 12 12.8 2 2.2
Other infections † 43 36.1 52 44.8 6 8.1 18 69.2 33 35.1 15 16.8
Grade 3-4 Transaminitis 33 27.7 29 25.0 4 5.4 26 100.0 20 21.3 15 16.8
Grade 3-4 
hyperbilirubinemia
3 2.5 4 3.4 1 1.3 5 19.2 1 1.1 0 0.0
Grade 3-4 Cardiotoxicity 0 0.0 2 1.7 0 0.0 7 26.9 5 5.3 0 0.0
Grade 3-4 mucositis 1 0.8 4 3.4 2 2.7 5 19.2 7 7.4 0 0.0
Fungal infection 16 13.4 43 37.1 0 0.0 3 11.5 14 15.1 4 4.5
Positive galactomannan 2 1.7 6 5.2 0 0.0 1 3.8 1 1.1 0 0.0
Death 2 1.7 2 1.7 0 0.0 5 19.2 2 2.1 0 0.0
PICU: pediatric intensive care unit.
* In IB protocol to cytarabine and in blocks to E. coli asparaginase.
† Infections with clinical diagnosis, without identified pathogen and antibiotic treatment.
Source: Own elaboration based on the data obtained in the study.




Induction IB Protocol mM Blocks II Phase A II Phase B
SR IR HR SR IR HR SR IR HR SR IR HR SR IR HR
% % % % % % % % % % % % % % %
Transfusional 
requirement
81.8 93.1 97.1 100.0 98.6 96.9 9.0 4.8 96.1 45.5 23.8 40.0 63.6 63.3 83.3
Thrombosis 0.0 12.3 5.7 0.0 1.4 0.0 0.0 0.0 15.4 0.0 1.6 0.0 0.0 0.0 0.0
Allergy * 0.0 0.0 0.0 0.0 1.4 6.2 0.0 0.0 53.8 18.2 0.0 0.0 0.0 0.0 0.0
Febrile neutropenia 63.6 57.5 65.7 100.0 82.2 84.4 18.2 7.9 100.0 72.7 58.7 75.0 54.5 26.6 50.0
Grade 3-4 infections 9.0 20.5 28.6 18.2 35.6 31.2 0.0 1.6 76.9 27.3 20.6 20.0 18.2 3.3 16.7
PICU 0.0 5.5 20.0 0.0 15.1 21.9 0.0 0.0 50.0 9.1 7.9 25.0 0.0 0.0 11.1
Other infections † 18.2 31.5 51.4 54.5 41.1 93.7 18.2 3.2 73.1 63.6 22.2 50.0 18.2 8.3 38.9
Grade 3-4 
Transaminitis
9.1 32.9 22.8 54.5 21.9 31.2 9.1 4.8 100.0 45.5 41.3 30.0 45.5 25.0 22.2
Grade 3-4 
hyperbilirubinemia
0.0 0.0 8.6 0.0 4.1 3.1 9.1 0.0 19.2 0.0 1.6 0.0 0.0 0.0 0.0
Grade 3-4 
Cardiotoxicity 
0.0 0.0 0.0 0.0 1.4 3.1 0.0 0.0 26.9 0.0 0.0 5.0 0.0 0.0 0.0
Grade 3-4 mucositis 0.0 0.0 2.8 9.1 2.7 3.1 9.1 1.6 19.2 9.1 6.2 10.0 0.0 0.0 0.0
Fungal infection 9.1 16.4 8.6 63.6 30.1 43.7 0.0 0.0 11.5 18.2 7.9 30.0 0.0 3.3 11.1
Positive 
galactomannan 
0.0 1.4 2.8 27.3 2.7 3.1 0.0 0.0 3.8 9.1 0.0 0.0 0.0 0.0 0.0
Death 0.0 0.0 5.7 0.0 1.4 3.1 0.0 0.0 19.2 0.0 3.1 0.0 0.0 0.0 0.0
SR: standard risk; IR: intermediate risk; HR: high risk; PICU: pediatric intensive care unit. 
* In IB protocol to cytarabine and in blocks E. coli asparaginase 
† Infections with clinical diagnosis, without identified pathogen and antibiotic treatment.
Source: Own elaboration based on the data obtained in the study.
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Comparison with previous studies
After comparing the adverse reactions to chemotherapy drugs 
observed in this study (ALL IC-BFM 2009 protocol) with those 
reported in the Intercontinental Trial BFM ALL IC 2002 (9) 
(Table 6), the main findings were lower incidence of infections 
for all risks —demarcated as an identified infection pathogen 
requiring antibiotics IV or septic shock— and increased 
incidence of liver toxicity and mucositis in the Intercontinental 
Trial BFM ALL IC 2002. 
Table 6. Comparison of incidence of grade 3 and 4 non-hematologic complications.
 
 
Standard risk Intermediate risk High risk
ALL IC-BFM 2009 
Protocol
(%)
BFM ALL IC-2002 
Protocol
(%)
ALL IC-BFM 2009 
Protocol
(%)
BFM ALL IC-2002 
Protocol
(%)
ALL IC-BFM 2009 
Protocol
(%)
BFM ALL IC-2002 
Protocol
(%)
Infections 9.0 22.8 11.4 19.2 26.9 40.3
Transaminitis 11.3 13.8 11.8 11.6 21.9 25.0
Hyperbilirubinemia 0.0 0.0 0.8 1.9 3.4 6.5
Cardiotoxicity 0.0 0.5 0.0 0.9 3.4 0.0
Mucositis 3.4 3.6 1.5 7.3 3.4 27.9
Source: Own elaboration based on the data obtained in the study.
Interim survival analysis in the sample
Overall survival at the moment of this evaluation was 79.9%, 
similar for patients with phenotype B and T. According to the risk, 
survival was 100% for standard risk, 85.4% for intermediate risk 







































73.3 (60.9 - 82.3)
30
Time (months)

















79.5 (39.3 - 94.5)
79.9 (69.1- 87.3)
30
Phenotype B Phenotype T
Time (months)

















62.5 (41 - 78.1)
85.4 (72.4 - 92.6)
30
Standard R. Intermediate R. High R.
Figure 1. Probability of 2-years survival curves. Source: Own elaboration based on the data obtained in the study.
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Discussion
Acute lymphoblastic leukemia is the most common malignancy 
in children (1); although overall cure rates have improved in high-
income countries, most patients live in low-income countries, where 
the possibility of cure is much lower (2). 
Comparing the mortality results found in this study with those 
reported in Latin America (2) and with specific numbers of Colombia 
(6,11), lower incidence of death during induction is observed; a possible 
explanation is that the patients of this protocol are hospitalized during 
the first month of treatment for the induction phase, so the detection 
and treatment of complications is timely. 
The pediatric oncology unit of service of Fundación HOMI has 
evaluated death induction along different ALL protocols based on 
the BFM strategy: 9.6% during 1996-2000, 6.5% after this, and 
3.5% for the previous protocol to BFM ALL IC 2012. Support 
measures and experience with the protocol during induction may 
explain the decline in death. 
When the incidence of death in induction and death in complete 
remission is compared against the Intercontinental Trial BFM ALL 
IC 2002 (9), no significant differences are observed in the mortality 
rate (2.77% vs. 1.67%).
Seven relapses (5.9%) occurred: two after completing treatment 
at 26 and 30 months after diagnosis, and five during treatment. The 
factors assessed, and that may have contributed to relapse, included 
two patients with positive minimal residual disease (MRD) at the 
end of induction, which increases risk of relapse as demonstrated in 
multiple studies (12,13).
Another factor that may be related is the intensity of treatment: 
three of the seven patients who relapsed experienced delays (one 
for medical reasons and two by administrative constraints). The 
remaining four underwent appropriate treatment intensity and did 
not experience unjustified delays. The study by Suarez et al. (6) 
showed that a four-week or longer delay for initiation of treatment 
phase Protocol II, was associated with lower survival at two years 
(67% vs. 88%, p=0.016); it was also evident that, regardless the 
cause of the delay, this is associated with lower survival.
The incidence of abandonment was lower than that reported 
by previous studies in Bogotá (5% vs. 9%) (6): previous data in the 
institution showed 25% of abandonment. This decrease could be 
related to regulatory strategies —guidelines for attention of leukemias 
in children— that have been implemented within the institution by a 
multidisciplinary team, which accompanies the patient and provides 
psychosocial support in order to ensure that patients understand 
the importance of compliance and to achieve full management of 
the disease in a single institution, according to the directions of the 
current regulation for the attention of children with leukemia.
This study identifies in detail, and for the first time, adverse reactions 
related to chemotherapy drugs, since information that describes 
complications related to the treatment of ALL in children is not found 
in previous publications in Colombia. Deaths, both during induction 
and complete remission, were all caused by sepsis and occurred more 
frequently in high risk patients during the consolidation blocks. 
A study conducted in Central America (2) reported that the 
incidence of death related to treatment in patients during complete 
remission was lower than what was found in this investigation 
(7.7% vs. 3.8%), which can be explained by late consultation or 
failure to deliver timely treatment to patients during episodes of 
febrile neutropenia. Death related to treatment, without detailed 
description of the causes, has been reported in previous assessments 
published about ALL in Colombia, where protocols of lower 
treatment intensity were used and rates of 6.17% and 3% were 
reported in the study by Buendía et al. (11) and by Suarez et al., 
respectively (6). 
The comparison of toxicity reported in this research with the 
Intercontinental Trial BFM ALL IC 2009 (Table 6) shows that the 
incidence of grade 3-4 infections or septic shock was lower for all 
risks. This may be related to a very low percentage of microbial 
agent identification. The incidence of liver toxicity and mucositis 
was higher in the Intercontinental Trial BFM ALL IC 2002, which 
has no clear explanation. 
The most frequent complications included febrile neutropenia, 
found in most patients during phase IB regardless of risk stratification, 
in all high risk patients during consolidation and in phase A 
of Protocol II. This complication allowed anticipating all the 
recommendations on fever and consultation to emergency care, as 
well as the administration of antibiotics within two hours. 
One of the limitations of this study, when evaluating the overall 
and event-free survival, was that this research is an interim evaluation 
of the implementation of a protocol, so the follow up is of maximum 
of 34 months; however, it is very important for childhood cancer 
treatment centers to make these assessments, particularly aiming at 
more intensive treatment strategies. This study shows 73.3% event-
free survival rate —considering abandonment as an event— at 
two years, which is higher than the 67% reported by an evaluation 
conducted at the National Cancer Institute in Colombia (6). 
The results of this evaluation have allowed taking actions to reduce 
deaths during complete remission: on the one hand, education to 
caregivers about fever and signs for early consultation to emergency 
room and, on the other, implementation of a protocol of febrile 
neutropenia with priority attention and administration of antibiotics 
within two hours of consultation in the emergency room, and at the 
onset of fever in hospitalized patients. In addition, abandonments 
are strictly followed by the institution and informed to the insurance 
company of the patient for active search. 
The results show a decrease in mortality during induction; 
treatment-related mortality is within expectations of an intensive 
chemotherapy protocol and strategies are being implemented to 
reduce these numbers. Abandonment is below 10%, and follow-up 
time is still short; however, overall and event-free survival is higher 
than that in previous treatment protocols.
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